According to a Page One story in the March 3rd edition of The Wall Street Journal, "The Food and Drug Administration has bungled its effort to build a new system for detecting the side effects of medicines after they go on the market, delaying its implementation by at least four years, according to a report commissioned by the agency itself."
But what is entirely missing from the story (by the generally excellent reporter Anna Mathews) is that the FDA has never been given a budget to build a new system.
Want better adverse event reporting? Want better post-marketing surveillance? Want better data mining opportunities?
Show me the money!
But what is entirely missing from the story (by the generally excellent reporter Anna Mathews) is that the FDA has never been given a budget to build a new system.
Want better adverse event reporting? Want better post-marketing surveillance? Want better data mining opportunities?
Show me the money!
